Polyphor Ltd, a clinical-stage biopharmaceutical company focused on the discovery and development of inno-vative antibiotics and other specialty pharma products for severe or life-threatening diseases, today announces the launch of its initial public offering (“IPO”) and its listing on the SIX Swiss Exchange. The price range for the offered shares has been set at CHF 30 to CHF 40 per share and the Company is targeting gross proceeds of approximately CHF 100 million to CHF 150 million which would primarily be used to fund the continued development of Polyphor’s lead product candidate murepavadin towards regulatory approval and further progress the development of balixafortide. The offering is comprised solely of a primary offering with no secondary share sales. VISCHER AG is acting as Swiss legal counsel to the issuer with Matthias Staehelin (Partner, Corporate) as team leader, Benedict Christ (Partner, Corporate), Angelo Imperiale (Associate, Corporate), Luzius Zumstein (Associate, Corporate), Nadia Tarolli (Partner, Tax) and Adrian Briner (Associate, Tax).